HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marketing In Brief

This article was originally published in The Rose Sheet

Executive Summary

Christian Dior: Firm's Capture R60/80 XP anti-aging skin-care range, available now at Dior beauty counters nationwide, incorporates adult stem cells "able to repair tissue, create new cells and even regenerate an organ" to fill wrinkles and put off the signs of aging, according to the company. The technology "takes effect almost instantly, smoothing over the skin's surface to fill in wrinkles and drive the liposome to the skin's lower layers," Dior says. "One hour after applying the product, wrinkles are visibly reduced, and after six hours, the skin becomes more smooth and taut as cell regeneration is activated," firm claims, noting that within six months of use, as many as 100 million new cells are generated. Capture R60/80 XP comes in a Rich Crème, a Serum and an Eye Crème for $80, $90 and $60, respectively

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel